Cell surface carbohydrates as prognostic markers in human carcinomas

Journal of Pathology

Volumn 179, Issue 4, 1996, Pages 358-369

  Dabelsteen, Erik ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cancer; Carbohydrates; Prognosis

Indexed keywords

BLOOD GROUP ABH ANTIGEN; CARBOHYDRATE; CELL ADHESION MOLECULE; SELECTIN;

CANCER; CELL SURFACE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

ABO BLOOD-GROUP SYSTEM; ANTIGENS, CD15; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; DISEASE PROGRESSION; HUMANS; MUCINS; NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 0029813776     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199608)179:4<358::AID-PATH564>3.0.CO;2-T     Document Type: Review

References (141)

1. Coon JS, Weinstein RS. Blood group-related antigens as markers of malignant potential and heterogeneity in human carcinomas. Hum Pathol 1986; 17: 1089-1106.
2. Hanski C, Drechsler K, Hanisch F-G, et al. Altered glycosylation of the MUC-1 protein core contributes to the colon carcinoma-associated increase of mucin-bound sialyl-Lewis x expression. Cancer Res 1993; 53: 4082-4088.
3. Dennis JW. Changes in glycosylation associated with malignant transformation and tumor progression. In: Fukuda M, ed. Cell Surface Carbohydrates and Cell Development. Boca Raton: CRC Press, 1992; 162-194.
4. Sell S. Cancer-associated carbohydrates identified by monoclonal antibodies. Hum Pathol 1990; 21: 1003-1019.
5. Singhal AK. Histo-blood group antigens in cancer. Cancer Biol 1991; 2: 379-388.
6. Hirszfeld L, Halber W, Laskowski J. Untersuchungen über die serologischen Eigenschaften der Gewebe. Z Immun 1929; 64: 61-80.
7. Thomsen O. Untersuchungen über die serologische Gruppendifferenzierung des Organismus. Acta Pathol Microbiol Scand Sect A 1930; 7: 250-257.
8. Hakomori S, Koscielak J, Bloch KJ, Jeanloz RW. Studies on immunological relation between the tumor glycolipids and blood group substances. J Immunol 1967; 98: 31-38.
9. Hakomori S. Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Adv Cancer Res 1989; 52: 257-331.
10. Dabelsteen E, Vedtofte P, Hakomori S, Young WW Jr. Accumulation of a blood group antigen precursor in oral premalignant lesions. Cancer Res 1983; 43: 1452-1454.
11. Dabelsteen E, Graem N, Clausen H, Hakomori S. Structural variations of blood group A antigens in human normal colon and carcinomas. Cancer Res 1988; 48: 181-187.
12. Hakomori S. Monoclonal antibodies directed to cell-surface carbohydrates. In: Kennett, Bechtol, McKearn, eds. Monoclonal Antibodies and Functional Cell Lines. New York: Plenum Press, 1984; 67-100.
13. Fukuda M. Cell surface carbohydrates: cell-type specific expression. In: Fukuda M, Hindsgaul O, eds. Molecular Glycobiology. New York: Oxford University Press, 1994; 1-52.
14. Samuelsson BE, Breimer ME. ABH antigens: some basic aspects. Transplant Proc 1987; 19: 4401-4407.
15. Roth J, Lentze MJ, Berger E. Immunocytochemical demonstration of ecto-galatosyltransferase in absorptive intestinal cells. J Cell Biol 1985; 100: 118-125.
16. Mandel U. Carbohydrates in oral epithelia and secretions: variation with cellular differentiation. APMIS 1992; 100 (Suppl 27): 119-129.
17. Oriol R, LePendu J, Mollicone R Genetics of ABO, H, Lewis, X. and related antigens. Vox Sang 1986; 51: 161-171.
18. Dabelsteen E, Mandel U, Clausen H. Cell surface carbohydrates are markers of differentiation in human oral epithelium. CRC Crit Rev Oral Biol Med 1991; 2: 493-507.
19. Feizi T. Demonstration by monoclonal antibodies that carbohydrate structures of glycoproteins and glycolipids are onco-developmental antigens. Nature 1985; 314: 53-57.
20. Fenderson BA, Eddy EM, Hakomori S. Glycoconjugate expression during embryogenesis and its biological significance. BioEssays 1990; 12: 173-179.
21. Mandel U, Petersen OW, Sørensen H, et al. Simple mucin-type carbohydrates in oral stratified squamous and salivary gland epithelia. J Invest Dermatol 1991; 97: 713-721.
22. Hakomori S, Kannagi R. Glycolipids as tumor-associated and differentiation markers. J Natl Cancer Inst 1983; 71: 323.
23. Fenderson BA, Andrews PW. Carbohydrate antigens of embryonal carcinoma cells: changes upon differentiation. APMIS 1992; 100: 109-118.
24. Takahashi I, Maehara Y, Kusumoto T, et al. Predictive value of preoperative serum sialyl Tn antigen levels in prognosis of patients with gastric cancer. Cancer 1993; 72: 1836-1840.
25. Hakomori S. Aberrant glycosylation in cancer cell membranes as focused on glycolipids: overview and perspectives. Cancer Res 1985; 45: 2405-2414.
26. Singhal AK, Ørntoft TF, Nudelman E, et al. Profiles of Lewis x-containing glycoproteins and glycolipids in sera of patients with adenocarcinoma. Cancer Res 1990; 50: 1375-1380.
27. Kouri M, Nordling S, Kuusela P, Pyrhönen S. Poor prognosis associated with elevated serum CA 19-9 level in advanced colorectal carcinoma, independent of DNA ploidy or SPF. Eur J Cancer 1993; 29A: 1691-1696.
28. Hakomori S. Role of gangliosides in tumor progression. Prog Brain Res 1994; 101: 241-250.
29. Herlyn M, Rodeck U, Koprowski H. Shedding of human tumor-associated antigens in vitro and in vivo. In: Klein G, Weinhouse S, eds. Advances in Cancer Research. Orlando: Academic Press, 1987; 189-221.
30. Ørntoft TF, Bech E. Circulating blood group related carbohydrate antigens as tumour markers. Glyco J 1995; 12.
31. Hakomori S. Glycosphingolipids in cellular interaction, differentiation, and oncogenesis. Annu Rev Biochem 1981; 50: 733-764.
32. Clausen H, Hakomori S. ABH and related histo-blood group antigens; immunochemical differences in carrier isotypes and their distribution. Vox Sang 1989; 56: 1-20.
33. Muramatsu T. Carbohydrate signals in metastasis and prognosis of human carcinomas. Glycobiol 1993; 3: 291-296.
34. Nakagoe T, Fukushima K, Hirota M, et al. An immunohistochemical study of the distribution of blood group substances and related antigens in primary colorectal carcinomas and metastatic lymph node and liver lesions, using monoclonal antibodies against A, B, H type 2, Lea, and Lex antigens. J Gastroenterol 1994; 29: 265-275.
35. Itzkowitz SH. Carbohydrate changes in colon carcinoma. APMIS 1992; 100 (Suppl 27): 173-180.
36. Idikio HA, Manickavel V. Lewis blood group antigens (a and b) in human breast tissues. Cancer 1991; 68: 1303-1308.
37. Juhl BR, Hartzen SH, Hanau B. A, B, H antigen expression in transitional cell carcinomas of the urinary bladder. Cancer 1986; 57: 1768-1775.
38. Aprikian AG, Sarkis AS, Reuter VE, Cordon-Cardo C, Sheinfeld J. Biological markers of prognosis in transitional cell carcinoma of the bladder: current concepts. Semin Urol 1993; 11: 137-144.
39. Kay HEM, Wallace DM. A and B antigens of tumours arising from urinary epithelium. J Natl Cancer Inst 1961; 26: 1349-1365.
40. Sheinfeld J, Reuter VE, Fair WR, Cordon-Cardo C. Expression of blood group antigens in bladder cancer: current concepts. Semin Surg Oncol 1992; 8: 308-315.
41. Ørntoft TF. Carbohydrate changes in bladder carcinomas. APMIS 1992; 100 (Suppl 27): 181-187.
42. Decenzo JM, Howard P, Irish CE. Antigenic deletion and prognosis of patients with stage A transitional cell bladder carcinoma. J Urol 1975; 114: 874-878.
43. Lange PH, Limas C, Fraley EE. Tissue blood-group antigens and prognosis in low stage transitional cell carcinoma of the bladder. J Urol 1978; 119: 52-55.
44. Bergman S, Javadpour N. The cell surface antigen A, B or O(H) as an indicator of malignant potential in stage A bladder carcinoma: preliminary report. J Urol 1978; 119: 49-51.
45. Limas C, Lange P, Fraley EE, Vessella RL. A, B, H antigens in transitional cell tumors of the urinary bladder. Correlation with the clinical course. Cancer 1979; 44: 2099-2107.
46. Emmott RC, Javadpour N, Bergman SM, Soares T. Correlation of the cell surface antigens with stage and grade in cancer of the bladder. J Urol 1979; 121: 37-39.
47. Young AK, Hammond E, Middleton AW Jr. The prognostic value of cell surface antigens in low grade, non-invasive, transitional cell carcinoma of the bladder. J Urol 1979; 122: 462-464.
48. Johnson JD, Lamm DL. Prediction of bladder tumor invasion with the mixed cell agglutination test. J Urol 1980; 123: 25-28.
49. Richie JP, Blute RD Jr, Waisman J. Immunologic indicators of prognosis in bladder cancer: the importance of cell surface antigens. J Urol 1980; 123: 22-24.
50. Newman AJ Jr, Carlton CE Jr, Johnson S. Cell surface A, B or O(H) blood group antigens as an indicator of malignant potential in stage A bladder carcinoma. J Urol 1980; 124: 27-29.
51. D'Elia FL, Cooper HS, Mulholland SG. ABH isoantigens in stage 0 papillary transitional cell carcinoma of the bladder: correlation with biological behavior. J Urol 1982; 127: 665-667.
52. Juhl BR, Hartvig Hartzen S, Hainau B. A, B, H antigen expression in transitional cell carcinomas of the urinary bladder. Cancer 1986; 57: 1768-1775.
53. Ørntoft TF. Expression and biosynthesis of ABH-related carbohydrate antigens in normal and pathologic human urothelium. APMIS 1990; 98 (Suppl 17): 5-34.
54. Stephenson TJ, Williams JL, Gelsthorpe K. Monoclonal antibodies to detect A, B and H blood group isoantigens in superficial transitional cell carcinoma of the bladder: a means of predicting invasive recurrences. Br J Urol 1985; 57: 148-153.
55. Cordon-Cardo C, Lloyd KO, Finstad CL, et al. Immunoanatomic distribution of blood group antigens in the human urinary tract: influence of secretor status. Lab Invest 1986; 55: 444-454.
56. Juhl BR. Methodologic and genetic influence on immunohistochemical demonstration and semiquantitation of blood group antigen A in human ureter urothelium. J Histochem Cytochem 1985; 33: 21-26.
57. Sanders H, McCue P, Graham SD. ABO(H) antigens and beta-2 microglobulin in transitional cell carcinoma. Cancer 1991; 67: 3024-3028.
58. Carey TE, Nair TS, Chern C, et al. Blood group antigens and integrins as biomarkers in head and neck cancer: is aberrant tyrosine phosphorylation the cause of altered a6β4 integrin expression? J Cell Biochem 1993; 17F: 223-232.
59. Dabelsteen E, Fejerskov O. Loss of epithelial blood group antigen-A during wound healing in oral mucous membrane. APMIS 1974; 84: 431-434.
60. Bryne M. Prognostic value of various molecular and cellular features in oral squamous cell carcinomas: a review. J Oral Pathol Med 1991; 20: 413-420.
61. To ACW, Soong S, Shingleton HM, et al. Immunohistochemistry of the blood group A,B,H, isoantigens and Oxford Ca antigen as prognostic markers for stage 1B squamous cell carcinoma of the cervix. Cancer 1986; 58: 2435-2439.
62. Matsumoto H, Muramatsu H, Shimotakahara T, et al. Correlation of expression of ABH blood group carbohydrate antigens with metastatic potential in human lung carcinomas. Cancer 1993; 72: 75-81.
63. Lee JS, Ro JY, Sahin AA, et al. Expression of blood-group antigen A - a favorable prognostic factor in non-small-cell lung cancer. N Engl J Med 1991; 324: 1084-1090.
64. Battifora H, Sorensen HR, Mehta P, et al. Tumor-associated antigen 43-9F is of prognostic value in squamous cell carcinoma of the lung. Cancer 1992; 70: 1867-1872.
65. b antigens with survival in patients with carcinoma of the lung. N Engl J Med 1992; 327: 14-18.
66. Miyake M, Hakomori S. A specific cell surface glycoconjugate controlling cell motility: evidence by functional monoclonal antibodies that inhibit cell motility and tumor cell metastatis. Biochemistry 1991; 30: 3328-3334.
67. Dabelsteen E, Mandel U, Therkildsen MH. Aberrant glycosylation in oral carcinomas. J Dent Res 1993; 72: 338 (Abstract).
68. Mollicone R, Dalix MA, Jacobsson A, et al. Red cell H-deficient, salivary ABH secretor phenotype of Reunion Island. Genetic control of the expression of H antigen in the skin. Glycoconjugate J 1988; 5: 499-512.
69. Oriol R, Mollicone R, Coullin P, Dalix A-M, Candelier J-J. Genetic regulation of the expression of ABH and Lewis antigens in tissues. APMIS 1992; 100 (Suppl 27): 28-38.
70. x-related antigen expression in human malignant and nonmalignant colonic tissues. Cancer Res 1986; 46: 2627-2632.
71. Fenderson BA, Holmes EH, Fukushi Y, Hakomori S. Coordinate expression of X and Y haptens during murine embryogenesis. Dev Biol 1986; 114: 12-21.
72. Lasky LA. Selectins: interpreters of cell-specific carbohydrate information during inflammation. Science 1992; 258: 964-969.
73. Hakomori S. Le-x and related structures as adhesion molecules. Histochem J 1992; 24: 771-776.
74. Hoff SD, Matsushita Y, Ota DM, et al. Increased expression of sialyldimeric Le-x antigen in liver metastases of human colorectal carcinoma. Cancer Res 1989; 49: 6883-6888.
75. Matsushita Y, Cleary KR, Ota DM, Hoff SD, Irimura T. Sialyl-dimeric Lewis-x antigen expressed on mucin-like glycoproteins in colorectal cancer metastases. Lab Invest 1990; 636: 780-791.
76. x antigens in primary colorectal, carcinomas and lymph node and hepatic lesions. J Gastroenterol 1994; 29: 129-138.
77. Matsusako T, Muramatsu H, Shirahama T, Muramatsu T, Ohi Y. Expression of a carbohydrate signal, sialyl dimeric Le-x antigen, is associated with metastatic potential of transitional cell carcinoma of the human urinary bladder. Biochem Biophys Res Commun 1991; 181: 1218-1222.
78. Nakamori S, Kameyama M, Imaoka S, et al. Increased expression of sialyl Lewis-x antigen correlates with poor survival in patients with colorectal carcinoma: clinicopathological and immunohistochemical study. Cancer Res 1993; 53: 3632-3637.
79. x antigen in relation to survival of patients with colorectal carcinoma. Cancer 1993; 72: 2323-2330.
80. Narita T, Funahashi H, Satoh Y, Watanabe T, Sakamoto J, Takagi H. Association of expression of blood group-related carbohydrate antigens with prognosis in breast cancer. Cancer 1993; 71: 3044-3054.
81. Jergensen T, Berner AA, Kaalhus O, Tveter KJ, Danielsen HE, Bryne M. Up-regulation of the oligosaccharide sialyl Lewis-x: a new prognostic parameter in metastatic prostate cancer. Cancer Res 1995; 55: 1817-1823.
82. x (defined by MAb FH6) and LCP. Clin Exp Metastasis 1991; 9: 245-257.
83. Hoff SD, Irimura T, Matsushita Y, Ota DM, Cleary KR, Hakomori S. Metastatic potential of colon carcinoma. Expression of ABO/Lewis-related antigens. Arch Surg 1990; 125: 206-209.
84. x antigen. Exp Cell Res 1991; 196: 20-25.
85. Saito O, Wang W-C, Lotan R, Fukuda M. Differential glycosylation and cell surface expression of lysosomal membrane glycoproteins in sublines of a human colon cancer exhibiting distinct metastatic potentials. J Biol Chem 1992; 267: 5700-5711.
86. Takada A, Ohmori K, Yoneda T, et al. Contribution of carbohydrate antigens sialyl Lewis A and sialyl Lewis X to adhesion of human cancer cells to vascular endothelium. Cancer Res 1993; 53: 354-361.
87. Dejana E, Martin-Padura I, Lauri D, et al. Endothelial leukocyte adhesion molecule- dependent adhesion of colon carcinoma cells to vascular endothelium is inhibited by an antibody to Lewis fucosylated type 1 carbohydrate chain. Lab Invest 1991; 66: 324-330.
88. Arends JW, Wiggers T, Verstijnen C, Hilgers J, Bosman FT. Gastrointestinal cancer-associated antigen (GICA) immunoreactivity in colorectal carcinoma in relation to patient survival. Int J Cancer 1984; 34: 193-196.
89. Walker RA, Day SJ. Expression of the antigen detected by the monoclonal antibody Ca 19.9 in human breast tissues. Virchows Arch 1986; 409: 375-383.
90. Sawada R, Lowe JB, Fukuda M. E-selectin-dependent adhesion efficiency of colonic carcinoma cells is increased by genetic manipulation of their cell surface lysosomal membrane glycoprotein-1 expression levels. J Biol Chem 1993; 268: 12675-12681.
91. x determinant on myeloid and tumor cells. Science 1990; 250: 1132-1135.
92. Lowe JB, Stoolman LM, Nair RP, Larsen RD, Berhend TL, Marks RM. ELAM-1-dependent cell adhesion to vascular endothelium determined by a transfected human fucosyltransferase cDNA. Cell 1990; 63: 475-484.
93. x is recognized by the endothelial cell leukocyte adhesion molecule ELAM-1. J Biol Chem 1991; 266: 14869-14872.
94. Springer TA, Lasky LA. Sticky sugars for selectins. Nature 1991; 349: 196-197.
95. Osborn L. Leukocyte adhesion to endothelium in inflammation. Cell 1990; 62: 3-6.
96. Brandley BK, Swiedler SJ, Robbins PW. Carbohydrate ligands of the LEC cell adhesion molecules. Cell 1990; 63: 861-863.
97. Gahmberg CG, Kotovuori P, Tontti E. Cell surface carbohydrate in cell adhesion. Sperm cells and leukocytes bind to their target cells through specific oligosaccharide ligands. APMIS 1992; 100 (Suppl 27): 39-52.
98. Varki A. Selectin ligands. Proc Natl Acad Sci USA 1994; 91: 7390-7397.
99. Iwai K, Ishikura H, Kaji M, et al. Importance of E-selectin (ELAM-1) and sialyl Lewis A in the adhesion of pancreatic carcinoma cells to activated endothelium. Int J Cancer 1993; 54: 972-977.
100. x bind ELAM-1. Glycobiol 1991; 1: 318-320.
101. Kojima N, Handa K, Newman W, Hakomori S. Inhibition of selectin-dependent tumor cell adhesion to endothelial cells and platelets by blocking O-glycosylation of these cells. Biochem Biophys Res Commun 1992; 182: 1288-1295.
102. Rice GE, Bevilacqua MP. An inducible endothelial cell surface glycoprotein mediates melanoma adhesion. Science 1989; 246: 1303-1306.
103. x. Science 1990; 250: 1130-1131.
104. x, and sulfated glycans modulate this binding. Biochem Biophys Res Commun 1991; 181: 1223-1230.
105. Hakomori S. New directions in cancer therapy based on aberrant expression of glycosphingolipids: anti-adhesion and ortho-signalling therapy. Cancer Cells 1991; 3: 461-470.
106. Del Villano BC, Brennan S, Brock P, et al. Radioimmunometric assay for a monoclonal antibody-defined tumor marker. Clin Chem 1983; 29: 549-552.
107. Sawada T, Ho JJL, Chung Y, Sowa M, Kim YS. E-selcctin binding by pancreatic tumor cells is inhibited by cancer sera. Int J Cancer 1994; 57: 901-907.
108. Dennis JW, Lafert S, Waghorne C, Breitman ML, Kerbel RS. Beta1-6 branching of Asn-linked oligosaccharides is directly associated with metastasis. Science 1987; 236: 582-585.
109. Gendler SJ, Spicer AP, Lalani E-N, et al. Structure and biology of a carcinoma-associated mucin MUCI. Am Rev Respir Dis 1991; 144: 42-47.
110. Carraway KL, Hull SR. Cell surface mucin-type glycoproteins and mucin-like domains. Glycobiol 1991; 1: 131-138.
111. Ho SB, Kim YS. Carbohydrate changes and cancer-associated mucin-like molecules. Semin Cancer Biol 1992; 2: 389-400.
112. Bhavanandan VP. Cancer-associated mucins and mucin-type glycoproteins. Glycobiol 1991; 1: 493-503.
113. Taylor-Papadimitriou J, Peat N, Graham R, Burchell J. Aberrant glycosylation of the MUC1 gene product in adenocarcinomas: implications for immunotherapy. In: Bock K, Clausen H, eds. Complex Carbohydrates in Drug Research. Structural and Functional Aspects. Copenhagen: Munksgaard, 1994; 382-393.
114. Dahiya R, Itzkowitz SH, Byrd JC, Kim YS. Mucin oligosaccharide biosynthesis in human colonic cancerous tissues and cell lines. Cancer 1992; 70: 1467-1476.
115. Ogata S, Ho I, Chen A, et al. Tumor-associated sialylated antigens are constitutively expressed in normal human colonic mucosa. Cancer Res 1995; 55: 1869-1874.
116. Springer GF, Desai PR, Banatwala I. Blood group MN specific substances and precursors in normal and malignant human breast tissue. Naturwissenschaften 1974; 61: 457-458.
117. Springer GF, Taylor CR, Howard DR, et al. Tn, a carcinoma-associated antigen, reacts with anti-Tn of normal human sera. Cancer 1985; 55: 561-569.
118. Springer GF. T and Tn, general carcinoma autoantigens. Science 1984; 224: 1198-1206.
119. Thor A, Ohuchi N, Szpak CA, Johnston WW, Schlom J. Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Res 1986; 46: 3118-3124.
120. Itzkowitz SH, Kjeldsen T, Friera A, Hakomori S, Yang US, Kim YS. Expression of Tn, sialosyl Tn, and T antigens in human pancreas. Gastroenterology 1991; 100: 1691-1700.
121. MacLean GD, Reddish M, Bowen-Yacyshyn MB, Poppema S, Longenecker BM. Active specific immunothrrapy against adenocarcinomas. Cancer Invest 1994; 12: 46-56.
122. Itzkowitz SH, Bloom EJ, Kokal WA, Modin G, Hakomori S, Kim YD. Sialosyl-Tn. A novel mucin antigen associated with prognosis in colorectal cancer patients. Cancer 1990; 66: 1960-1966.
123. Werther JL, Rivera-MacMurray S, Bruckner H, Tatematsu M, Itzkowitz SH. Mucin-associated sialosyl-Tn antigen expression in gastric cancer correlates with an adverse outcome. Br J Cancer 1994; 69: 613-616.
124. David L, Nesland JM, Clausen H, Carneiro F, Sobrinhoe-Simoes M. Simple mucin-type carbohydrate antigens (Tn, sialosyl-Tn and T) in gastric mucosa, carcinomas and metastases. APMIS 1992; 100 (Suppl 27): 162-172.
125. Wulff HF. Rational Diagnosis and Treatment. An Introduction to Clinical Decision-making. 2nd edn. Oxford: Blackwell Scientific Publications, 1976
126. Ikeda Y, Kuwano H, Baba K, et al. Expression of sialyl-Tn antigens in normal squamous epithelium, dysplasia, and squamous cell carcinoma in the esophagus. Cancer Res 1993; 53: 1706-1708.
127. Ogawa H, Inoue M, Tanizawa O, Miyamoto M, Sakurai M. Altered expression of sialyl-Tn, Lewis antigens and carcinoembryonic antigen between primary and metastatic lesions of uterine cervical cancers. Histochemistry 1992; 97: 311-317.
128. Gravdahl C, Dabelsteen E, Koppang HS, Kjoerheim Å, Bryne M. A carbohydrate, sialosyl-Tn, is a marker for an altered, non-malignant activity in squamous epithelium in the head and neck region? J Pathol (in press).
129. Fukutomi T, Hirohashi S, Tsuda H, et al. The prognostic value of tumor-associated carbohydrate structures correlated with gene amplifications in human breast carcinomas. Jpn J Surg 1991; 21: 499-507.
130. Miles DW, Happerfield LC, Smith P. et al. Expression of sialyl-Tn predicts the etlect of adjuvant chemotherapy in node-positive breast cancer. Br J Cancer 1994; 70: 1272-1275.
131. Hamada S, Kamada M, Hirao T, Aono T. High expression rate of Tn antigen in metastatic lesions of uterine cervical cancers. Cancer Lett 1993; 74: 167-173.
132. Hirao T, Sakamoto Y, Kamada M, Hamada S, Aono T. Tn antigen, a marker of potential for metastasis of uterine cervix cancer cells. Cancer 1993; 72: 154-159.
133. Lehman TP, Cooper HS, Mulholland SG. Peanut lectin binding sites in transitional cell carcinoma of the urinary bladder. Cancer 1984; 53: 272.
134. Summers JL, Coon JS, Ward RM, Fator WH, Miller AW III, Weinstein RS. Prognosis in carcinoma of the urinary bladder based upon tissue blood group ABH and Thomsen-Friedenreich antigen status and karyotype of the initial tumor. Cancer Res 1983; 48: 934-939.
135. Coon JS, Weinstein RS, Summers JL. Blood group precursor T-antigen expression in human urinary bladder carcinoma. Am J Clin Pathol 1982; 77: 692-699.
136. Nishiyama T, Matsumoto Y, Watanabe H, Fujiware M, Sato S. Detection of Tn antigen with Vicia villosa agglutinin in urinary bladder cancer: its relevance to the patient's clinical course. J Natl Cancel Inst 1987; 78: 1113-1125.
137. Ohoka H, Shinomiya H, Yokoyama M, Ochi K, Takeuchi M, Utsumi S. Thomsen-Friedenreich antigen in bladder tumors as detected by specific antibody; a possible marker of recurrence. Urol Res 1985; 13: 47-50.
138. Langkilde NC, Wolf H, Clausen H, Kjeldsen T, Ørntoft TF. Nuclear volume and expression of T-antigen, sialosyl-Tn-antigen, and Tn-antigen in carcinoma of the human bladder. Cancer 1992; 69: 219-227.
139. Juhl BR, Hartzen SH, Hainau B. Thomsen-Triedenrcich-relaled antigen in non-neoplastic ureter urothelium and transitional cell tumours of the urinary bladder. An immunohistochemical study employing the monoclonal antibody 49H.8. APMIS 1987; 95: 83-91.
140. Fernandes B, Sagman U, Auger M, Demetrio M, Dennis JW. Beta1-6 branched oligosaccharides as a marker of tumor progression in human breast and colon neoplasia. Cancer Res 1991; 51: 718-723.
141. Debray H, Qin L, Delannoy P, et al. Altered glycosylation of membrane glycoproteins in human uroepithelial cell lines. Int J Cancer 1986; 37: 607.